Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases. The big pharma, known as ...

Under the agreement, the Chinese biotech has granted MSD an exclusive global license to develop, manufacture, and commercialise HS-10535, whilst retaining the option to co-promote or solely ...

MSD CEO Robert Davis also addressed growing concerns about trade policy, as the US government moved forward with a Section 232 investigation into pharmaceutical imports – a precursor to potential ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Templeton, vice president, pharmaceutical sciences, MSD Research Laboratories. Meribel Pharma Solution, a new mid-size CDMO, has launched with an integrated network across Europe. The firm has ten ...

[Photo provided to chinadaily.com.cn] United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple ...

Evaxion Biotech AS (NASDAQ:EVAX) entered into a transformational partnership with MSD in September 2024, which is tracking well towards potential option exercise in the second half of 2025. The ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The 470,000ft² facility is set to bolster the company's biologics and ...